Under the Production Linked Incentive (PLI) Scheme for promotion of domestic manufacturing of critical Key Starting Materials (KSMs)/Drug Intermediates (DIs) and Active Pharmaceutical Ingredients (APIs) in India, 48 projects have been approved. 

The scheme aims to avoid disruption in supply of critical active pharmaceutical ingredients (APIs) used to make critical drugs for which there are no alternatives by reducing supply disruption risk due to excessive dependence on single source. 

Products notified and approved under the scheme prior to commencement of production under the PLI scheme were primarily imported. As of December 2024, against an investment commitment of Rs. 3,938.5 crore over the period of six years, investment of Rs. 4,254 crore has already been made under the scheme.

As a result of the scheme, cumulative sales of Rs. 1,556 crore have been reported over the period from the beginning of the scheme till December 2024, including exports of Rs. 412 crore, thereby avoiding imports worth Rs. 1,144 crore and creating domestic manufacturing capacity for 25 identified KSMs/DIs/APIs.